AG7088

AG7088

A rhinovirus 3C protease inhibitor (anti-viral) intended for use on the common cold. It made it as far as Phase II trials before Agouron stopped development.
References in periodicals archive ?
In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.
They believe the virus could be treated by a modified version of an experimental common cold drug called AG7088.
Agouron's rhinovirus 3C protease inhibitor AG7088 is in human clinical trials for the proposed treatment of the common cold.
The American drug company Agouron Pharmaceuticals have come closest with a drug called AG7088 that stops the cold virus reproducing.
Currently in Phase II studies, AG7088 could enter large scale Phase III clinical studies later this year and possibly lead to an NDA by the end of 2001.